Liberum Capital Kept Genus PLC (LON:GNS) As “Hold”; Has Price Objective Of GBX 2100.00; Biomarin Pharmaceutical (BMRN) Has 1.13 Sentiment

They currently have a GBX 2100.00 TP on Genus PLC (LON:GNS). Liberum Capital’s target would suggest a potential downside of -6.50% from the company’s close price. This was released in a research report on Monday, 12 February.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $14.11 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

Among 8 analysts covering Genus PLC (LON:GNS), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Genus PLC has GBX 2600 highest and GBX 1424 lowest target. GBX 2097.13’s average target is -6.63% below currents GBX 2246 stock price. Genus PLC had 100 analyst reports since July 27, 2015 according to SRatingsIntel. Liberum Capital maintained the stock with “Buy” rating in Monday, November 9 report. The rating was maintained by Liberum Capital with “Buy” on Monday, September 4. The firm has “Buy” rating by Liberum Capital given on Monday, August 22. The stock of Genus plc (LON:GNS) has “Buy” rating given on Thursday, February 1 by Peel Hunt. Liberum Capital maintained the shares of GNS in report on Monday, October 12 with “Buy” rating. The stock of Genus plc (LON:GNS) earned “Hold” rating by Liberum Capital on Monday, February 27. Liberum Capital maintained the shares of GNS in report on Monday, February 1 with “Hold” rating. N+1 Singer maintained the stock with “Hold” rating in Thursday, February 23 report. On Monday, October 30 the stock rating was maintained by Liberum Capital with “Hold”. Liberum Capital maintained the shares of GNS in report on Monday, January 11 with “Hold” rating.

Genus plc, together with its subsidiaries, engages in the application of quantitative genetics and biotechnology for animal breeding in the porcine and bovine sectors. The company has market cap of 1.38 billion GBP. It operates through three divisions: Genus PIC, Genus ABS, and Research and Development. It has a 42.38 P/E ratio. The firm sells sows, boars, and semen under the PIC name to breed pigs with various characteristics for pork production.

The stock increased 0.18% or GBX 4 during the last trading session, reaching GBX 2246. About 3,688 shares traded. Genus plc (LON:GNS) has 0.00% since February 12, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report earnings on February, 22. They expect $-0.24 earnings per share, up 35.14% or $0.13 from last year’s $-0.37 per share. After $-0.07 actual earnings per share reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts 242.86% negative EPS growth.

Since January 1, 0001, it had 0 insider buys, and 9 sales for $9.10 million activity.

Palo Alto Investors Llc holds 9.56% of its portfolio in BioMarin Pharmaceutical Inc. for 2.44 million shares. Baker Bros. Advisors Lp owns 5.91 million shares or 4.46% of their US portfolio. Moreover, Venbio Select Advisor Llc has 4.32% invested in the company for 597,972 shares. The Quebec – Canada-based Sectoral Asset Management Inc has invested 2.86% in the stock. Tang Capital Management Llc, a California-based fund reported 90,215 shares.